DR. CHARLES EDWARD STEWART M.D.
Prescription History 1609824366
Emergency Medicine in Tulsa, OK

NPI Status: Active since May 05, 2006

Contact Information

10909 S QUEBEC PL
TULSA, OK
ZIP 74137
Phone: (918) 296-3789

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. CHARLES EDWARD STEWART M.D., an active Emergency Medicine specialist practicing in Tulsa, OK. Our medical registry currently tracks 5 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 97 documented patient claims. Among these therapy options, the most frequently utilized medication is Clindamycin Hcl, which accounts for 33 claims alone.

Medication Index


Amoxicillin-Clavulanate Potass

Generic Formulation: Amoxicillin/Potassium ClavSpecialty: Emergency Medicine
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 113
OK State Average Benchmarks
Peer Average Claims24.0
Peer Average 30-Day Fills24.6
Peer Average Days Supply232
Conservative Utilization

This provider writes prescriptions for this formulation 50.0% less frequently than the standard regional baseline metric for practitioners inside OK. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $302.01 across this reporting matrix range.

Provider Avg Cost Per Claim

$25.17

State Avg Cost Per Claim

$14.00

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A fixed-ratio combination of amoxicillin trihydrate and potassium clavulanate.

Therapeutic Applications

Amoxicillin/clavulanic acid is a combination penicillin-type antibiotic used to treat a wide variety of bacterial infections. It works by stopping the growth of bacteria. This antibiotic treats only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.

Clindamycin Hcl

Generic Formulation: Clindamycin HclSpecialty: Emergency Medicine
Provider Metrics Summary
Total Claims 33
30-Day Fills 33.0
Days Supply 430
OK State Average Benchmarks
Peer Average Claims21.0
Peer Average 30-Day Fills22.0
Peer Average Days Supply171
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 57.1% higher than the standard regional baseline profile for OK. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $551.26 across this reporting matrix range.

Provider Avg Cost Per Claim

$16.70

State Avg Cost Per Claim

$11.52

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An antibacterial agent that is a semisynthetic analog of LINCOMYCIN.

Therapeutic Applications

Clindamycin is used to treat a wide variety of bacterial infections. It is an antibiotic that works by stopping the growth of bacteria. This antibiotic treats only bacterial infections. It will not work for virus infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.

Mupirocin

Generic Formulation: MupirocinSpecialty: Emergency Medicine
Provider Metrics Summary
Total Claims 17
30-Day Fills 17.0
Days Supply 280
OK State Average Benchmarks
Peer Average Claims26.0
Peer Average 30-Day Fills26.8
Peer Average Days Supply388
Conservative Utilization

This provider writes prescriptions for this formulation 34.6% less frequently than the standard regional baseline metric for practitioners inside OK. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $147.29 across this reporting matrix range.

Provider Avg Cost Per Claim

$8.66

State Avg Cost Per Claim

$11.78

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A topically used antibiotic from a strain of Pseudomonas fluorescens. It has shown excellent activity against gram-positive staphylococci and streptococci. The antibiotic is used primarily for the treatment of primary and secondary skin disorders, nasal infections, and wound healing.

Therapeutic Applications

Mupirocin is used to treat certain skin infections (such as impetigo). It is an antibiotic. It works by stopping the growth of certain bacteria.

Sulfamethoxazole-Trimethoprim

Generic Formulation: Sulfamethoxazole/TrimethoprimSpecialty: Emergency Medicine
Provider Metrics Summary
Total Claims 21
30-Day Fills 21.3
Days Supply 350
OK State Average Benchmarks
Peer Average Claims27.0
Peer Average 30-Day Fills30.4
Peer Average Days Supply418
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across OK. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $118.24 across this reporting matrix range.

Provider Avg Cost Per Claim

$5.63

State Avg Cost Per Claim

$6.82

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A drug combination with broad-spectrum antibacterial activity against both gram-positive and gram-negative organisms. It is effective in the treatment of many infections, including PNEUMOCYSTIS PNEUMONIA in AIDS.

Therapeutic Applications

This medication is a combination of two antibiotics: sulfamethoxazole and trimethoprim. It is used to treat a wide variety of bacterial infections (such as middle ear, urine, respiratory, and intestinal infections). It is also used to prevent and treat a certain type of pneumonia (pneumocystis-type). This medication should not be used by children less than 2 months of age due to the risk of serious side effects. This medication treats only certain types of infections. It will not work for viral infections (such as flu). Unnecessary use or misuse of any antibiotic can lead to its decreased effectiveness.

Toujeo Solostar

Generic Formulation: Insulin Glargine,hum.Rec.AnlogSpecialty: Emergency Medicine
Provider Metrics Summary
Total Claims 14
30-Day Fills 14.0
Days Supply 311
OK State Average Benchmarks
Peer Average Claims20.0
Peer Average 30-Day Fills33.2
Peer Average Days Supply945
Conservative Utilization

This provider writes prescriptions for this formulation 30.0% less frequently than the standard regional baseline metric for practitioners inside OK. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $5,476.38 across this reporting matrix range.

Provider Avg Cost Per Claim

$391.17

State Avg Cost Per Claim

$734.18

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A recombinant LONG ACTING INSULIN and HYPOGLYCEMIC AGENT that is used to manage BLOOD GLUCOSE in patients with DIABETES MELLITUS.

Therapeutic Applications

Insulin glargine is used with a proper diet and exercise program to control high blood sugar in people with diabetes. Controlling high blood sugar helps prevent kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems. Proper control of diabetes may also lessen your risk of a heart attack or stroke. Insulin glargine is a man-made product that is similar to human insulin. It replaces the insulin that your body would normally make. It acts longer than regular insulin, providing a low, steady level of insulin. It works by helping blood sugar (glucose) get into cells so your body can use it for energy. Insulin glargine may be used with a shorter-acting insulin product. It may also be used alone or with other diabetes drugs. This monograph is about the following insulin glargine products: insulin glargine, insulin glargine-yfgn.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. CHARLES EDWARD STEWART M.D. provides transparency into local medical care patterns within Tulsa, OK.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Emergency Medicine** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.